5 High Yielding Stocks that Raised their Dividends by 50% over the last five years - 24/7 Wall St.[S&P 5006,868.40 -0.41%][Dow Jones48,882.40 -0.91%][Nasdaq 10024,948.00 -0.19%][Russell 20002,630.80 -1.35%][FTSE 10010,903.30 +0.43%][Nikkei 22558,763.70 +0.21%][Stock Market Live February 27, 2026: S&P 500 (SPY) Swimming in Red][Investing]# 5 High Yielding Stocks that Raised their Dividends by 50% over the last five years### Quick ReadHome Depot raised its dividend 55% over five years despite housing market w ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Small-Cap Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Longleaf experienced several environments throughout its experience in small-cap investing. This year, the underlying developments in the Fund’s holdings were more promising than the actual stock price returns when compared to the target of inflation plus 10% and the unusual performance of the Russell 2000. In Q4 2025, the Fund returned ...

Core Insights - Humana reported a wider fourth-quarter loss due to rising medical costs impacting margins in its core Medicare Advantage business [1] Company Summary - The increase in medical costs has been a significant factor contributing to the company's financial performance challenges [1]

These Buffett stocks could easily beat the market over the next 12 months.Sure, Warren Buffett has passed the torch as Berkshire Hathaway's (BRK.A +0.96%) (BRK.B +1.35%) CEO to Greg Abel. However, I still view all of the stocks currently in Berkshire's portfolio as Buffett stocks. They were all either personally picked by the legendary investor or by someone else operating under his watchful eye.Quite a few of the stocks Berkshire Hathaway owns are good picks right now. Here are three Buffett stocks to buy ...

Core Insights - The stock market has experienced significant volatility in January, particularly affecting major healthcare insurers due to news regarding Medicare reimbursement rates [1] Group 1: Industry Impact - Major healthcare insurers, including UnitedHealth Group, have seen their stock prices shaken by recent developments in Medicare reimbursement rates [1] Group 2: Analyst Background - Gary Alexander, with extensive experience in technology and healthcare sectors, has been a contributor to Seeking Alpha since 2017 and has provided insights on industry trends [1]

Core Viewpoint - The healthcare sector, particularly healthcare insurance stocks, is experiencing significant downward pressure following a proposed rate announcement for Medicare Advantage, resulting in a loss of approximately $90 billion in market capitalization [2][4]. Group 1: Market Reaction - The announcement of the new proposed Medicare Advantage rate was a surprise to insurers, leading to a substantial decline in stock prices, with Humana down 21% and United Health down 19% [4]. - The proposed rate increase was significantly lower than expected, with a midpoint of 5% but coming in at less than 1%, causing a negative market reaction [6][11]. Group 2: Financial Implications - If the proposed rates are finalized, insurers could face a 15-20% decrease in earnings from Medicare Advantage [5]. - United Health's earnings report indicated progress, but the anticipated annual revenue contraction was not well-received by investors [9][10]. Group 3: Company-Specific Insights - United Health's Medicare Advantage segment is just one part of its business, which also includes a large commercial insurance segment and Optum Health [8]. - The company is currently in a transition phase, focusing on margin recovery in its commercial insurance business and expecting membership declines [9].

Core Viewpoint - The ongoing lawsuit against Humana Inc. involves allegations of securities law violations, particularly regarding the company's assurances about healthcare demand and profitability amidst rising medical costs due to pent-up demand following COVID-19 restrictions [2][3]. Group 1: Lawsuit Background - A Humana investor filed a lawsuit in June 2024, claiming that the company misled investors about the impact of pent-up demand for healthcare services on its financial performance [2]. - The lawsuit alleges that Humana downplayed the pressures on its adjusted EPS from increased medical costs, contrary to its assurances that there was no significant pent-up demand affecting utilization rates [2]. Group 2: Legal Proceedings - A consolidated amended complaint was filed on November 20, 2024, and the defendants submitted a motion to dismiss the complaint on April 24, 2025 [3]. - Investors who purchased shares of Humana Inc. prior to July 2022 are encouraged to contact the Shareholders Foundation for potential options related to the lawsuit [1][3].

Market Overview - The S&P 500 has increased by 17% over the past year and 2.5% over the past month, currently surpassing the 6,950 mark with 7,300 as a potential target [1] - A rotation is occurring in the market, with mega-cap tech stocks cooling while overall breadth improves, indicating a shift towards more diverse growth across small caps and energy stocks [2] - Despite modest upside forecasts for the S&P 500 in 2026, rising valuation metrics and ongoing volatility may lead to selective trimming of positions [2][3] Company-Specific Insights Tesla (TSLA) - Tesla shares are currently trading at $440, down approximately 9% over the last month, facing rising price pressures and increased competition, particularly from BYD in China [4] - Deliveries fell by about 8.6% year-over-year, and the Cybertruck is underperforming in sales volume [4] - Major fund managers, including ARK Innovation ETF, are reducing their Tesla holdings, indicating a lack of confidence in the stock's future performance [4] GE HealthCare Technologies (GEHC) - GE HealthCare Technologies is trading at $82 per share, with sales in China declining by approximately 11% and 18% year-over-year in the first and second quarters of 2024, respectively [6] - The company has been downgraded by UBS due to competitive pressures and risks from rising generics that are not fully priced in [6] - Despite a steady dividend payout of 0.18%, the stock faces limited upside and increased competition in the medical technology market [8] UnitedHealth (UNH) - UnitedHealth shares are trading at less than $340, down 34% over the past year, primarily due to rising medical costs and a significant drop in Medicaid margins projected to decline from -0.1% in 2025 to -1.8% in 2026 [9] - The company has faced management challenges, including curbing earnings guidance and scrutiny over diagnosis practices, leading to increased uncertainty [10] - Analysts suggest selling UNH shares until clearer visibility on its performance emerges [10]

Core Viewpoint - Guizhou Province has been continuously deepening its medical insurance system reform, focusing on people's health and creating a multi-layered medical security network that covers all citizens, reduces out-of-pocket expenses, and enhances access to healthcare services [4][6]. Group 1: Medical Insurance Reform - The implementation of family pooling for personal medical insurance accounts allows family members, including extended relatives, to share medical expenses, improving the efficiency of insurance fund usage [5]. - The establishment of a comprehensive database for universal insurance coverage has maintained over 41 million insured individuals, with reimbursement rates for inpatient care at approximately 83% for employee insurance and 73% for resident insurance [6]. Group 2: Accessibility and Convenience - The introduction of a "mobile medical insurance station" service model allows village doctors to visit patients at home, facilitating immediate medical insurance settlements [5]. - The integration of artificial cochlear implants into the medical insurance reimbursement system has significantly reduced the cost of the devices from nearly 300,000 yuan to under 50,000 yuan, making them more accessible for families of hearing-impaired children [7]. Group 3: Efficiency in Medical Services - The province has implemented a "one person, one file" system for insurance registration, enhancing the quality and coverage of insurance [6]. - The transition to a prepayment and immediate settlement model for basic medical insurance has reduced the reimbursement processing time from 30 working days to just 1 working day [8]. Group 4: Digital Transformation - The development of a multi-channel, integrated service system for medical insurance has enabled 39.6 million people to activate their insurance codes, with over 10,925 medical institutions offering "face-scan payment" options [10]. - The implementation of a drug traceability system, where each medication has a unique traceability code, has improved transaction efficiency and customer satisfaction in pharmacies [9]. Group 5: Future Directions - The Guizhou medical insurance department plans to continue deepening reforms, enhance the multi-layered insurance system, and promote provincial-level coordination of basic medical insurance to improve the public's sense of security and satisfaction with medical insurance services [10].

Core Insights - Cigna Group (CI) is a major player in the insurance industry, with a market cap of $74.6 billion, offering a range of insurance products including life, accident, disability, supplemental, Medicare, and dental insurance [1] Financial Performance - Analysts anticipate that Cigna will report a profit of $7.90 per share for Q4 2025, reflecting a 19% increase from $6.64 per share in the same quarter last year [2] - For the full fiscal year, Cigna's EPS is expected to be $29.63, an 8.4% increase from $27.33 in fiscal 2024, with a further rise to $30.56 projected for fiscal 2026 [3] Stock Performance - Cigna's stock has underperformed compared to the S&P 500 Index, which gained 16.9% over the past 52 weeks, while Cigna's shares only increased by 1.7% during the same period [4] - The stock also lagged behind the Health Care Select Sector SPDR Fund, which returned 13% in the same timeframe [4] Market Concerns - Investor concerns regarding Cigna's pharmacy-benefit management (PBM) business model have contributed to its underperformance, particularly due to a planned shift to a no-rebate pricing model by 2027 and the repricing of major contracts worth $90 billion in annual revenue, raising fears of transition risk and margin compression [5] Recent Earnings Report - On October 30, Cigna's shares fell over 17% despite reporting Q3 results that included an adjusted EPS of $7.83, surpassing Wall Street's expectations of $7.70, and adjusted revenue of $69.6 billion, exceeding the forecast of $67.2 billion [6] - Cigna expects its full-year adjusted EPS to be $29.60 [6] Analyst Ratings - The consensus opinion among analysts is bullish, with a "Strong Buy" rating overall; out of 23 analysts, 17 recommend a "Strong Buy," 2 suggest a "Moderate Buy," 3 give a "Hold," and 1 recommends a "Strong Sell" [7] - The average analyst price target for Cigna is $326.05, indicating a potential upside of 16.8% from current levels [7]